Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Nonpeptide CRF1 antagonist developed at Parke-Davis modulates brain NE levels

Nov. 11, 1998

Knoll develops potential new antipsychotic agent with advantages over available therapies

Nov. 10, 1998

LEF-553: a potent mu-opioid receptor agonist with peripheral analgesic effects

Nov. 10, 1998

NK1 antagonist L-732138 exhibits activity indicating efficacy in neuropathic pain

Nov. 10, 1998

Novel sodium channel blocker from Roche evaluated in vitro for neuroprotective efficacy

Nov. 10, 1998

Reversible mixed MAO-A/MAO-B inhibitor discovered at Synthelabo is presented this week

Nov. 10, 1998

RPR-118723: a novel anticonvulsant and potent glycine-site NMDA receptor antagonist

Nov. 10, 1998

Pfizer presents preclinical profile of potent, full 5-HT1D receptor antagonist

Nov. 10, 1998

Pharmacia & Upjohn patents new agents for CNS and neurodegenerative disorders

Nov. 10, 1998

Noncytotoxic thiocolchicine derivatives useful as muscle relaxants

Nov. 10, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 15, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...